A-423,579
A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.
Wikipage redirect
primaryTopic
A-423,579
A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.
has abstract
A-423,579 is one of a range of ...... ently in clinical development.
@en
IUPAC name
4-[4-[3-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]-3,5-difluorophenyl]benzonitrile
@en
thumbnail
Wikipage page ID
20,216,055
Wikipage revision ID
720,865,453
ImageName
Stereo, Kekulé, skeletal formula of A-423,579
imagesize
Verifiedfields
verifiedrevid
477,234,900
Watchedfields
hypernym
comment
A-423,579 is one of a range of ...... ently in clinical development.
@en
label
A-423,579
@en
